Review





Similar Products

proteases recombinant human mmp2  (Sino Biological)
94
Sino Biological proteases recombinant human mmp2
Proteases Recombinant Human Mmp2, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/proteases recombinant human mmp2/product/Sino Biological
Average 94 stars, based on 1 article reviews
proteases recombinant human mmp2 - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
human mmp 1 protein  (MedChemExpress)
93
MedChemExpress human mmp 1 protein
Human Mmp 1 Protein, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human mmp 1 protein/product/MedChemExpress
Average 93 stars, based on 1 article reviews
human mmp 1 protein - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
recombinant human mmp2  (Sino Biological)
94
Sino Biological recombinant human mmp2
Engineering and characterization of E. coli Nissle 1917 to express TME-responsive IL-15 (A) A <t>recombinant</t> plasmid (pNeae2) encoding conditionally released IL-15 protein was introduced into E. coli Nissle 1917 (EcN) and expressed on the bacterial outer membrane. (B and C) The expression of HA-tagged IL-15 in EcN-IL-15 was analyzed by flow cytometry and western blot. (D) Western blot analysis of the cleavage of EcN-IL-15 by recombinant proteases. (E–G) The isolated mouse splenocytes were labeled with CFSE and stimulated for 72 h with supernatant from <t>MMP2</t> cleavage of EcN or EcN-IL-15, followed by flow cytometry analysis and CCK8 assay ( n = 3). (H–J) EcN-IL-15 strains delayed tumor progression in vivo ( n = 4). (H) Treatment schedule of EcN-IL-15 in subcutaneous MC38 tumor. (I) MC38 tumor growth curves with different treatments (means ± SD). (J) Kaplan-Meier survival curves. (K) EcN-IL-15 reshapes the TME and boosts anti-tumor immune responses. Quantification of CD3 + T cells, CD4 + T cells, CD8 + T cells, NK cells, DCs, and macrophages in MC38 tumor tissues; n = 4 biological replicates. Data are presented as means ± SEM unless otherwise specified. p values were analyzed by one-way analysis of variance (ANOVA) with Tukey’s multiple comparisons test (G, K), two-way ANOVA with Tukey’s multiple comparisons test (I), or Mantel-Cox log rank test (J). ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001; ns, not significant.
Recombinant Human Mmp2, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant human mmp2/product/Sino Biological
Average 94 stars, based on 1 article reviews
recombinant human mmp2 - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
recombinant human mmp 12  (Sino Biological)
94
Sino Biological recombinant human mmp 12
Engineering and characterization of E. coli Nissle 1917 to express TME-responsive IL-15 (A) A <t>recombinant</t> plasmid (pNeae2) encoding conditionally released IL-15 protein was introduced into E. coli Nissle 1917 (EcN) and expressed on the bacterial outer membrane. (B and C) The expression of HA-tagged IL-15 in EcN-IL-15 was analyzed by flow cytometry and western blot. (D) Western blot analysis of the cleavage of EcN-IL-15 by recombinant proteases. (E–G) The isolated mouse splenocytes were labeled with CFSE and stimulated for 72 h with supernatant from <t>MMP2</t> cleavage of EcN or EcN-IL-15, followed by flow cytometry analysis and CCK8 assay ( n = 3). (H–J) EcN-IL-15 strains delayed tumor progression in vivo ( n = 4). (H) Treatment schedule of EcN-IL-15 in subcutaneous MC38 tumor. (I) MC38 tumor growth curves with different treatments (means ± SD). (J) Kaplan-Meier survival curves. (K) EcN-IL-15 reshapes the TME and boosts anti-tumor immune responses. Quantification of CD3 + T cells, CD4 + T cells, CD8 + T cells, NK cells, DCs, and macrophages in MC38 tumor tissues; n = 4 biological replicates. Data are presented as means ± SEM unless otherwise specified. p values were analyzed by one-way analysis of variance (ANOVA) with Tukey’s multiple comparisons test (G, K), two-way ANOVA with Tukey’s multiple comparisons test (I), or Mantel-Cox log rank test (J). ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001; ns, not significant.
Recombinant Human Mmp 12, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant human mmp 12/product/Sino Biological
Average 94 stars, based on 1 article reviews
recombinant human mmp 12 - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
recombinant human mmp-2  (PeproTech)
90
PeproTech recombinant human mmp-2
Engineering and characterization of E. coli Nissle 1917 to express TME-responsive IL-15 (A) A <t>recombinant</t> plasmid (pNeae2) encoding conditionally released IL-15 protein was introduced into E. coli Nissle 1917 (EcN) and expressed on the bacterial outer membrane. (B and C) The expression of HA-tagged IL-15 in EcN-IL-15 was analyzed by flow cytometry and western blot. (D) Western blot analysis of the cleavage of EcN-IL-15 by recombinant proteases. (E–G) The isolated mouse splenocytes were labeled with CFSE and stimulated for 72 h with supernatant from <t>MMP2</t> cleavage of EcN or EcN-IL-15, followed by flow cytometry analysis and CCK8 assay ( n = 3). (H–J) EcN-IL-15 strains delayed tumor progression in vivo ( n = 4). (H) Treatment schedule of EcN-IL-15 in subcutaneous MC38 tumor. (I) MC38 tumor growth curves with different treatments (means ± SD). (J) Kaplan-Meier survival curves. (K) EcN-IL-15 reshapes the TME and boosts anti-tumor immune responses. Quantification of CD3 + T cells, CD4 + T cells, CD8 + T cells, NK cells, DCs, and macrophages in MC38 tumor tissues; n = 4 biological replicates. Data are presented as means ± SEM unless otherwise specified. p values were analyzed by one-way analysis of variance (ANOVA) with Tukey’s multiple comparisons test (G, K), two-way ANOVA with Tukey’s multiple comparisons test (I), or Mantel-Cox log rank test (J). ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001; ns, not significant.
Recombinant Human Mmp 2, supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant human mmp-2/product/PeproTech
Average 90 stars, based on 1 article reviews
recombinant human mmp-2 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
recombinant human matrix metalloproteinase 2 protein  (Sino Biological)
94
Sino Biological recombinant human matrix metalloproteinase 2 protein
Engineering and characterization of E. coli Nissle 1917 to express TME-responsive IL-15 (A) A <t>recombinant</t> plasmid (pNeae2) encoding conditionally released IL-15 protein was introduced into E. coli Nissle 1917 (EcN) and expressed on the bacterial outer membrane. (B and C) The expression of HA-tagged IL-15 in EcN-IL-15 was analyzed by flow cytometry and western blot. (D) Western blot analysis of the cleavage of EcN-IL-15 by recombinant proteases. (E–G) The isolated mouse splenocytes were labeled with CFSE and stimulated for 72 h with supernatant from <t>MMP2</t> cleavage of EcN or EcN-IL-15, followed by flow cytometry analysis and CCK8 assay ( n = 3). (H–J) EcN-IL-15 strains delayed tumor progression in vivo ( n = 4). (H) Treatment schedule of EcN-IL-15 in subcutaneous MC38 tumor. (I) MC38 tumor growth curves with different treatments (means ± SD). (J) Kaplan-Meier survival curves. (K) EcN-IL-15 reshapes the TME and boosts anti-tumor immune responses. Quantification of CD3 + T cells, CD4 + T cells, CD8 + T cells, NK cells, DCs, and macrophages in MC38 tumor tissues; n = 4 biological replicates. Data are presented as means ± SEM unless otherwise specified. p values were analyzed by one-way analysis of variance (ANOVA) with Tukey’s multiple comparisons test (G, K), two-way ANOVA with Tukey’s multiple comparisons test (I), or Mantel-Cox log rank test (J). ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001; ns, not significant.
Recombinant Human Matrix Metalloproteinase 2 Protein, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant human matrix metalloproteinase 2 protein/product/Sino Biological
Average 94 stars, based on 1 article reviews
recombinant human matrix metalloproteinase 2 protein - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
recombinant human (rh) mmp-9  (AnaSpec)
90
AnaSpec recombinant human (rh) mmp-9
Engineering and characterization of E. coli Nissle 1917 to express TME-responsive IL-15 (A) A <t>recombinant</t> plasmid (pNeae2) encoding conditionally released IL-15 protein was introduced into E. coli Nissle 1917 (EcN) and expressed on the bacterial outer membrane. (B and C) The expression of HA-tagged IL-15 in EcN-IL-15 was analyzed by flow cytometry and western blot. (D) Western blot analysis of the cleavage of EcN-IL-15 by recombinant proteases. (E–G) The isolated mouse splenocytes were labeled with CFSE and stimulated for 72 h with supernatant from <t>MMP2</t> cleavage of EcN or EcN-IL-15, followed by flow cytometry analysis and CCK8 assay ( n = 3). (H–J) EcN-IL-15 strains delayed tumor progression in vivo ( n = 4). (H) Treatment schedule of EcN-IL-15 in subcutaneous MC38 tumor. (I) MC38 tumor growth curves with different treatments (means ± SD). (J) Kaplan-Meier survival curves. (K) EcN-IL-15 reshapes the TME and boosts anti-tumor immune responses. Quantification of CD3 + T cells, CD4 + T cells, CD8 + T cells, NK cells, DCs, and macrophages in MC38 tumor tissues; n = 4 biological replicates. Data are presented as means ± SEM unless otherwise specified. p values were analyzed by one-way analysis of variance (ANOVA) with Tukey’s multiple comparisons test (G, K), two-way ANOVA with Tukey’s multiple comparisons test (I), or Mantel-Cox log rank test (J). ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001; ns, not significant.
Recombinant Human (Rh) Mmp 9, supplied by AnaSpec, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant human (rh) mmp-9/product/AnaSpec
Average 90 stars, based on 1 article reviews
recombinant human (rh) mmp-9 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
recombinant mmp 2  (Sino Biological)
94
Sino Biological recombinant mmp 2
Engineering and characterization of E. coli Nissle 1917 to express TME-responsive IL-15 (A) A <t>recombinant</t> plasmid (pNeae2) encoding conditionally released IL-15 protein was introduced into E. coli Nissle 1917 (EcN) and expressed on the bacterial outer membrane. (B and C) The expression of HA-tagged IL-15 in EcN-IL-15 was analyzed by flow cytometry and western blot. (D) Western blot analysis of the cleavage of EcN-IL-15 by recombinant proteases. (E–G) The isolated mouse splenocytes were labeled with CFSE and stimulated for 72 h with supernatant from <t>MMP2</t> cleavage of EcN or EcN-IL-15, followed by flow cytometry analysis and CCK8 assay ( n = 3). (H–J) EcN-IL-15 strains delayed tumor progression in vivo ( n = 4). (H) Treatment schedule of EcN-IL-15 in subcutaneous MC38 tumor. (I) MC38 tumor growth curves with different treatments (means ± SD). (J) Kaplan-Meier survival curves. (K) EcN-IL-15 reshapes the TME and boosts anti-tumor immune responses. Quantification of CD3 + T cells, CD4 + T cells, CD8 + T cells, NK cells, DCs, and macrophages in MC38 tumor tissues; n = 4 biological replicates. Data are presented as means ± SEM unless otherwise specified. p values were analyzed by one-way analysis of variance (ANOVA) with Tukey’s multiple comparisons test (G, K), two-way ANOVA with Tukey’s multiple comparisons test (I), or Mantel-Cox log rank test (J). ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001; ns, not significant.
Recombinant Mmp 2, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant mmp 2/product/Sino Biological
Average 94 stars, based on 1 article reviews
recombinant mmp 2 - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

Image Search Results


Engineering and characterization of E. coli Nissle 1917 to express TME-responsive IL-15 (A) A recombinant plasmid (pNeae2) encoding conditionally released IL-15 protein was introduced into E. coli Nissle 1917 (EcN) and expressed on the bacterial outer membrane. (B and C) The expression of HA-tagged IL-15 in EcN-IL-15 was analyzed by flow cytometry and western blot. (D) Western blot analysis of the cleavage of EcN-IL-15 by recombinant proteases. (E–G) The isolated mouse splenocytes were labeled with CFSE and stimulated for 72 h with supernatant from MMP2 cleavage of EcN or EcN-IL-15, followed by flow cytometry analysis and CCK8 assay ( n = 3). (H–J) EcN-IL-15 strains delayed tumor progression in vivo ( n = 4). (H) Treatment schedule of EcN-IL-15 in subcutaneous MC38 tumor. (I) MC38 tumor growth curves with different treatments (means ± SD). (J) Kaplan-Meier survival curves. (K) EcN-IL-15 reshapes the TME and boosts anti-tumor immune responses. Quantification of CD3 + T cells, CD4 + T cells, CD8 + T cells, NK cells, DCs, and macrophages in MC38 tumor tissues; n = 4 biological replicates. Data are presented as means ± SEM unless otherwise specified. p values were analyzed by one-way analysis of variance (ANOVA) with Tukey’s multiple comparisons test (G, K), two-way ANOVA with Tukey’s multiple comparisons test (I), or Mantel-Cox log rank test (J). ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001; ns, not significant.

Journal: Cell Reports Medicine

Article Title: Probiotic-mediated tumor microenvironment reprogramming with protease-sensitive interleukin-15 and photothermal therapy

doi: 10.1016/j.xcrm.2025.102191

Figure Lengend Snippet: Engineering and characterization of E. coli Nissle 1917 to express TME-responsive IL-15 (A) A recombinant plasmid (pNeae2) encoding conditionally released IL-15 protein was introduced into E. coli Nissle 1917 (EcN) and expressed on the bacterial outer membrane. (B and C) The expression of HA-tagged IL-15 in EcN-IL-15 was analyzed by flow cytometry and western blot. (D) Western blot analysis of the cleavage of EcN-IL-15 by recombinant proteases. (E–G) The isolated mouse splenocytes were labeled with CFSE and stimulated for 72 h with supernatant from MMP2 cleavage of EcN or EcN-IL-15, followed by flow cytometry analysis and CCK8 assay ( n = 3). (H–J) EcN-IL-15 strains delayed tumor progression in vivo ( n = 4). (H) Treatment schedule of EcN-IL-15 in subcutaneous MC38 tumor. (I) MC38 tumor growth curves with different treatments (means ± SD). (J) Kaplan-Meier survival curves. (K) EcN-IL-15 reshapes the TME and boosts anti-tumor immune responses. Quantification of CD3 + T cells, CD4 + T cells, CD8 + T cells, NK cells, DCs, and macrophages in MC38 tumor tissues; n = 4 biological replicates. Data are presented as means ± SEM unless otherwise specified. p values were analyzed by one-way analysis of variance (ANOVA) with Tukey’s multiple comparisons test (G, K), two-way ANOVA with Tukey’s multiple comparisons test (I), or Mantel-Cox log rank test (J). ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001; ns, not significant.

Article Snippet: Recombinant human MMP2, MMP9, and uPA were purchased from Sino Biological.

Techniques: Recombinant, Plasmid Preparation, Membrane, Expressing, Flow Cytometry, Western Blot, Isolation, Labeling, CCK-8 Assay, In Vivo